全文获取类型
收费全文 | 159224篇 |
免费 | 10292篇 |
国内免费 | 555篇 |
专业分类
耳鼻咽喉 | 1941篇 |
儿科学 | 4420篇 |
妇产科学 | 3057篇 |
基础医学 | 20683篇 |
口腔科学 | 2972篇 |
临床医学 | 18306篇 |
内科学 | 32571篇 |
皮肤病学 | 2498篇 |
神经病学 | 15260篇 |
特种医学 | 4853篇 |
外国民族医学 | 4篇 |
外科学 | 20984篇 |
综合类 | 2279篇 |
现状与发展 | 1篇 |
一般理论 | 222篇 |
预防医学 | 15429篇 |
眼科学 | 3353篇 |
药学 | 10713篇 |
2篇 | |
中国医学 | 240篇 |
肿瘤学 | 10283篇 |
出版年
2023年 | 702篇 |
2022年 | 1207篇 |
2021年 | 2815篇 |
2020年 | 1675篇 |
2019年 | 2763篇 |
2018年 | 3186篇 |
2017年 | 2388篇 |
2016年 | 2587篇 |
2015年 | 3206篇 |
2014年 | 4556篇 |
2013年 | 7045篇 |
2012年 | 10289篇 |
2011年 | 10965篇 |
2010年 | 6156篇 |
2009年 | 5741篇 |
2008年 | 10380篇 |
2007年 | 10932篇 |
2006年 | 10776篇 |
2005年 | 10906篇 |
2004年 | 10367篇 |
2003年 | 10067篇 |
2002年 | 9524篇 |
2001年 | 1386篇 |
2000年 | 1071篇 |
1999年 | 1518篇 |
1998年 | 2086篇 |
1997年 | 1772篇 |
1996年 | 1469篇 |
1995年 | 1415篇 |
1994年 | 1197篇 |
1993年 | 1206篇 |
1992年 | 910篇 |
1991年 | 837篇 |
1990年 | 800篇 |
1989年 | 746篇 |
1988年 | 672篇 |
1987年 | 650篇 |
1986年 | 628篇 |
1985年 | 764篇 |
1984年 | 977篇 |
1983年 | 982篇 |
1982年 | 1345篇 |
1981年 | 1211篇 |
1980年 | 1104篇 |
1979年 | 557篇 |
1978年 | 645篇 |
1977年 | 627篇 |
1976年 | 509篇 |
1975年 | 461篇 |
1974年 | 433篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
2.
3.
4.
5.
6.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 下载免费PDF全文
7.
Vestibular function laboratories utilize a multitude of diagnostic instruments to evaluate a dizzy patient. Caloric irrigators, oculomotor stimuli, and rotational chairs produce a stimulus whose accuracy is required for the patient response to be accurate. Careful attention to everything from cleanliness of equipment to threshold adjustments determine on a daily basis if patient data are going to be correct and useful. Instrumentation specifications that change with time such as speed and temperature must periodically be checked using calibrated instruments. 相似文献
8.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
9.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
10.